ACE inhibitor-induced angioedema

Curr Allergy Asthma Rep. 2012 Feb;12(1):72-8. doi: 10.1007/s11882-011-0238-z.


Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioedema / chemically induced*
  • Angioedema / diagnosis
  • Angioedema / epidemiology
  • Angioedema / therapy
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Causality
  • Comorbidity
  • Diagnosis, Differential
  • Humans
  • Prevalence
  • Skin Diseases / diagnosis
  • Urticaria / epidemiology


  • Angiotensin-Converting Enzyme Inhibitors